NEW YORK, June 14, 2013 /PRNewswire/ -- IntelliCell
BioSciences, Inc. ("Company") (OTC Pink: SVFC) announced today that
on May 14, 2013 through June 2, 2013, its cellular laboratory facility
underwent a thorough inspection by the FDA. The observations from
the FDA inspection were provided to the company in the Form 483.
The Company will respond to those observations in a timely manner.
IntelliCell will take the necessary actions to address the relevant
IntelliCell's Chairman and CEO, Dr. Steven Victor, stated,
"Our Company is very pleased that the FDA has inspected our new
flagship cellular laboratory. While there are many companies and
physicians' practices in the cellular/regenerative medicine space
that may attempt to avoid contact with the FDA, IntelliCell has
adopted a more transparent approach. We will continue to work hard
with the FDA to meet all cGTP requirements for the manufacturing of
Human Cells, Tissues, and Cellular and Tissue-Base Products
About IntelliCell BioSciences
IntelliCell BioSciences is a Regenerative Medicine
company developing novel technologies that address the
regenerative, curative and preventative conditions of disease
states with high unmet clinical needs. The Company has several
patent-pending applications and one published patent for an
industry unique method of
obtaining autologous stromal vascular fraction (SVF)
cells from the vasculature surrounding adipose tissue containing
adult stem cells and a robust population of regenerative healing
cells. The Company is also pioneering the development of autologous
and allogeneic cells from living and non-living tissue donors for
research purposes. IntelliCell is planning a series of
in-human clinical studies with top tier universities for the
treatment of osteoarthritis, multiple sclerosis, lower limb
ischemic wounds, and gum regeneration in the oral cavity as well as
medical aesthetics. The Company has developed a first in
class cGTP cellular processing facility in New York
City, purpose built and designed to be fully integrated into an
ambulatory surgery center.
Certain statements set forth in this press release constitute
"forward-looking statements." Forward-looking statements include,
without limitation, any statement that may predict, forecast,
indicate, or imply future results, performance or achievements, and
may contain the words "estimate," "project," "intend," "forecast,"
"anticipate," "plan," "planning," "expect," "believe," "will
likely," "will reach," "will change," "will soon," "should,"
"could," "would," "may," "can" or words or expressions of similar
meaning. Such statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause the
company's actual results and financial position to differ
materially from those included within the forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including those relating to the Company's ability to
grow its business. Actual results may differ materially from the
results predicted and reported results should not be considered as
an indication of future performance. The potential risks and
uncertainties include, among others, the Company's limited
operating history, the limited financial resources, domestic or
global economic conditions, activities of competitors and the
presence of new or additional competition, and changes in Federal
or State laws. More information about the potential factors that
could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
Anna Rhodes, IntelliCell
BioSciences, Inc. Phone: (646) 576-8710
Melissa Diaz, South Street Media,
Inc. Phone: (917) 937-8968
SOURCE IntelliCell BioSciences, Inc.